Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

Warning

This publication doesn't include Faculty of Economics and Administration. It includes Faculty of Medicine. Official publication website can be found on muni.cz.

Authors	LUDWIG Heinz ADAM Zdeněk TOTHOVÁ Elena HÁJEK Roman LABAR Boris EGYWD Miklós ŠPIČKA Ivan GISSLINGER Heinz DRACH Johannes KUHN Ingrid HINKE Axel ZOJER Niklas
Year of publication	2010
Type	Article in Periodical
Magazine / Source	Haematologica
MU Faculty or unit	Faculty of Medicine
Citation
Field	Oncology and hematology
Keywords	thalidomide; multiple myeloma; thalidomide-interferon; progression free survival
Description	Thalidomide maintenance therapy after stem cell transplantation resulted in increased progression-free survival and overall survival in a few trials, but its role in non-transplant eligible patients with multiple myeloma remains unclear. This study assessed the impact of thalidomide-interferon in comparison to interferon maintenance therapy in elderly patients with multiple myeloma.
Related projects:	University Research Centre - Czech Myeloma Group From classic prognostic markers to clinical applications in selected pharmacogenomic and pharmacoproteomic projects in multiple myeloma and monoclonal gammapathies